Plasma & Platelets
Transfusion transmitted bacterial infections in patients: why are they often undetected and underreported?
Dr. Richard J. Benjamin, MBChB, PhD, FRCPath
Cerus Corporation,
Concord, California, USA
Plasma
Assessment of plasma preparations in TTP
Prof. Dr. Paul Coppo, MD
CNR-MAT, AP-HP, Hóspital Saint-Antoine
Paris, France
Platelets
Ordering platelet concentrates: does pathogen inactivation matter to the clinician?
Prof. Dr. Helmut Ostermann
LMU Kliniken, University of Munich
Munich, Germany
Platelets
Safety surveillance and the introduction of pathogen reduced platelets: the role of national hemovigilance systems in the Cerus post-market clinical follow-up strategy
Dr. John Pitman, PhD
Cerus Corporation
Concord, USA
Platelets
What does published literature tell us about the clinical efficacy of INTERCEPT treated platelets?
Dr. Joan Cid Vidal
Hospital Clínic
Barcelona, Spain
Platelets
Clinical performance of INTERCEPT and solvent detergent plasma used with idiopathic thrombotic purpura patients requiring therapeutic plasma exchanges
Dr. Mario Ojeda-Uribe, MD
Groupe Hospitalier Region Mulhouse Sud-Alsace (GHRMSA), Hospital E. Muller
Mulhouse, France
Platelets
INTERCEPT treated platelets are effective in preventing bleeding
Ass. prof. Dr. Gerda Leitner
Medical University / General hospital Vienna
Vienna, Austria
Platelets & Plasma
